Document:

Amended and Restated Offer Letter dated as of September 11, 2007

 Exhibit 10.10 
  

			
	

	  	 2400 Bayshore Parkway
 Mountain View, CA 94043
 650.386.3100 Tel
 650.386.3101 Fax
 www.mappharma.com

 September 11, 2007 
 Anastasios Gianakakos 
 1045 Mason, Unit 202 
 San
Francisco, CA 94108 
 Dear Tassos: 
 This letter confirms the
terms of the offer we extended to you on September 16, 2006 with updates to certain terms and conditions to reflect the status of your employment as of the date of this letter. The terms and conditions specified in this letter are effective as
of September 30, 2006, your original start date. 
 Your title is Sr. Vice President, Business and Corporate Development reporting to me. Your starting
bi-weekly compensation on your start date was $9,038, annualized to $235,000. 
 On your start date, you were eligible for MAP’s bonus program, which is
currently an MBO based program with target goals set at 20%. This program is subject to annual review by the Board of Directors. 
 You have been given a
one-time sign-on bonus of $30,000, which has already been paid to you. In addition, the Company has reimbursed or will reimburse up to $10,000 for moving expenses for any move that relocates you closer to the MAP facility within the first twelve
months of your employment. To qualify for the reimbursement, you must submit valid receipts and any reimbursements will be paid to you as taxable income. Should you leave the company within the first twelve months of your employment, you will be
expected to repay MAP Pharmaceuticals, Inc. the full amount of the bonuses granted to you. 
 The Compensation Committee of MAP’s Board of Directors has
granted and MAP has issued options equal to 1.5% of outstanding shares (as of September 16, 2006) subject to standard vesting (# of shares and price set upon commencement of full time employment) to you in connection with your full time
employment. 
 As a MAP employee, you are also be eligible for full company benefits, which include Health, Dental, Life, Vision, Vacation and Holidays.

 Your offer was originally contingent upon your ability to show satisfactory proof of identity and authorization to work in the United States and upon the
successful completion of our employment background check and drug test. These contingencies have been met and cleared results have been received. 
 As
required, on your start date you executed the company’s Confidentiality and Assignment of Inventions Agreement, providing for protection of the company’s proprietary information and trade secrets. We ask that you continue to make every
effort to protect the confidential and proprietary information of MAP Pharmaceuticals, Inc. 

			
	

	  	 2400 Bayshore Parkway
 Mountain View, CA 94043
 650.386.3100 Tel
 650.386.3101 Fax
 www.mappharma.com

 Anastasios Gianakakos – Page 2 
 As part of your employment at MAP Pharmaceuticals, Inc., you have been required to attend Safety Training. Additional information has been given to you upon joining the
organization. 
 Tassos, we look forward to your continued contributions to the MAP Pharmaceuticals, Inc. team! We believe you will find that MAP
Pharmaceuticals, Inc. will continue to provide a unique and rewarding work experience. 
 Please contact me if you have any questions regarding your
employment. You may accept these terms and conditions by signing below and returning the signed copy, the second copy is for your records. 
  

	
	Sincerely,
	
	 /s/ Tim Nelson

	Tim Nelson
	President and Chief Executive Officer

 You understand that this letter is not a contract, expressed or implied, guaranteeing employment, or employment
for any duration. You further understand that you are an “at will” employee, and that your employment with MAP has been voluntarily entered into and will be for no specified period. As a result, you will be free to resign at any time, for
any reason or for no reason, as you deem appropriate. MAP will have a similar right, and may conclude our employment relationship with you at any time, with or without cause. Additionally, we may withdraw your employment at any time, with or without
notice to you. The provisions stated in this letter supersede all prior discussions and negotiations, and no other writing published by MAP Pharmaceuticals, Inc. is intended to modify the presumptions of at-will employment status. 
  

					
	Agreed and Accepted:	 		 	
			
	 /s/ Anastasios Gianakakos
	 		 	 September 19, 2007

	Anastasios Gianakakos	 		 	DateForm of Change in Control Agreement

 EXHIBIT 10.12 
 FORM OF CHANGE IN CONTROL AGREEMENT 
 THIS CHANGE IN CONTROL AGREEMENT
(“Agreement”) dated as of [                    ] (the “Effective Date”) is entered by and between
[            ] (“Executive”) and MAP Pharmaceuticals, Inc., a Delaware corporation (the “Company”). 
 WITNESSETH: 
 WHEREAS, Executive is a
senior executive of the Company and has made and is expected to continue to make major contributions to the short and long term profitability, growth and financial strength of the Company; 
 WHEREAS, the Company recognizes that the possibility of a Change in Control (as defined below) always exists; 
 WHEREAS, the Company desires to assure itself of both present and future continuity of management; 
 WHEREAS, the Company wishes to ensure that Executive is not practically disabled from discharging his duties in respect of a proposed or actual
transaction involving a Change in Control; and 
 WHEREAS, the Company desires to provide additional inducement for Executive to continue to
remain in the employ of the Company. 
 NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Company and Executive agree as follows: 
 1. Certain Defined Terms. In addition to terms defined
elsewhere herein, the following terms have the following meanings when used in this Agreement with initial capital letters: 
 (a)
“Board” shall mean the Board of Directors of the Company. 
 (b) “Cause” shall mean any one of the
following events: (i) the Executive’s violation, provided the Executive has received written notice from the Company and been given thirty (30) days in which to cure such failure (if curable), of any material provision of this
Agreement [or the Employment Agreement by and between the Company and the Executive dated (the “Employment Agreement”)], including, without limitation, the Executive’s continuing failure (after reasonable notice) to follow the
reasonable written instructions of the Company’s Chief Executive Officer, the Board or a committee thereof; (ii) any intentional or grossly negligent act or omission by the Executive that is reasonably likely to lead to the material injury
of the Company or its business, employees, customers or vendors, provided the Executive has received written notice from the Company and been given thirty (30) days in which to cure such act or omission (provided that such act or omission is
curable); (iii) the Executive’s material violation of any federal, state or local law applicable to the Company or its business, as initially determined by a court (for avoidance of doubt, a conviction of a material violation of any
federal, state or local law applicable to the Company or its business which is subsequently overturned by 

 
an appellate court shall remain Cause for termination); (iv) the Executive’s plea of guilty or nolo contendere to, or conviction of, a felony or of
a misdemeanor involving moral turpitude; or (v) the Executive’s failure to comply in any material respect with, provided the Executive has received written notice from the Company and been given thirty (30) days in which to cure such
failure (if curable), the written employee policies and procedures of the Company. 
 (c) The term “Change of
Control” means and includes each of the following: 
 (i) A transaction or series of transactions (other than an offering of the
Company’s stock to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any “person” or related “group” of “persons” (as such terms are used in Sections
13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction, directly or indirectly
controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the
total combined voting power of the Company’s securities outstanding immediately after such acquisition; or 
 (ii) During any period of
two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new director(s) (other than a director designated by a person who shall have entered into an agreement with the Company to effect a
transaction described in Section 1(c)(i) or Section 1(c)(iii) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who
either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or 
 (iii) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of
(x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company’s assets in any single transaction or series of related transactions or (z) the
acquisition of assets or stock of another entity, in each case other than a transaction: 
 A. Which results in the Company’s voting
securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or
indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or
indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction, and 
 B. After which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for
purposes of this Section 1(c)(iii)(B) as beneficially owning 50% or more of combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; or 
  

 2 

 (iv) The Company’s stockholders approve a liquidation or dissolution of the Company. 
 The Board shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has
occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters relating thereto. 
 (d) “Good Reason” shall mean the Executive’s voluntary termination, following (i) a reduction by the Company of Executive’s Base Salary except to the extent the annual base salary of all other
executives of the Company are similarly reduced; (ii) the taking of any action by the Company that would adversely affect Executive’s participation in, or reduce Executive’s benefits under, the Company’s benefit plans (including
under any equity compensation plan), except to the extent the benefits of all other executives of the Company are similarly reduced; [(iii) a breach by the Company of any material provision of the Employment Agreement by and between the Company and
the Executive dated [                    ], which breach remains uncured following 30 days after the Executive provides the Company with
written notice of the breach;] (iv) the assignment to Executive of any duties or responsibilities that results in any diminution or adverse change of Executive’s position, status, circumstances of employment or scope of responsibilities;
provided, however, that if following a change in control, the Company becomes a division of, or a business unit of another corporation or other business entity and the Executive remains the Executive Vice President and Chief Scientific
Officer of the division or business unit comprised of the Company, such changes of the Executive’s responsibilities of employment which would reflect these circumstances shall not be deemed to be a material diminution which would give rise, in
and of itself, to Good Reason; or (v) Executive’s refusal to relocate to a location more than twenty-five (25) miles from the Company’s location at the Effective Date. 
 2. Terminations In Connection With A Change In Control. Notwithstanding any provision to the contrary in any employment agreement, equity
compensation plan, equity award agreement or other Company severance plan, if Executive’s employment shall terminate involuntarily without Cause or for Good Reason during the 12 month period following a Change in Control, the Company shall:

 (a) Severance Payments: Pay to Executive an amount equal to the sum
of: (i) twelve (12) months then current base salary; and (ii) the target bonus otherwise payable to Executive pursuant to the Company’s performance-based compensation bonus plan with respect to the fiscal year in which
termination occurs, payable in a lump sum as soon as reasonably practicable, but in any event no later than two and one-half (2 1/2) months following the date of termination of employment. 
 (b) Continued Benefits. If
Executive elects to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) following such termination, then the Company shall pay Executive’s monthly COBRA
premium for continued health insurance coverage for Executive and Executive’s eligible dependents until the earlier of (i) twelve (12) months following the termination date, or (ii) the date upon which Executive and his eligible
dependents become eligible for comparable coverage under a group health insurance plan maintained by subsequent employer. 
  

 3 

 (c) Equity Awards. The Company shall cause all outstanding equity awards then held by
Executive (including, without limitation, stock options, stock appreciation rights, phantom shares, restricted stock or similar awards) to become fully vested and, if applicable, exercisable with respect to all the shares subject thereto effective
immediately prior to the date of termination. In all other respects, such awards will continue to be subject to the terms and conditions of the plans, if any, under which they were granted and any applicable agreements between the Company and
Executive. 
 (d) Attorneys Fees. The Company shall pay Executive’s attorneys fees to negotiate, review and advise
Executive regarding the Release set forth in Section 3(a) of this Agreement, up to a maximum of $1,000. 
 3. Conditions to
Receipt of Severance. 
 (a) Separation Agreement and Release of Claims. The receipt of any severance pursuant to
Section 2 will be subject to Executive signing within 90 days following the date of termination of employment, and not subsequently revoking, a separation agreement and release of claims in a form acceptable to the Company. No severance
pursuant to Section 2 will be paid or provided until the separation agreement and release of claims becomes effective. 
 (b)
Section 409A. Notwithstanding the forgoing, however, to the extent required to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), if Executive is deemed to be a “specified
employee” for purposes of Section 409A(a)(2)(B) of the Code, Executive agrees that the payments due to Executive under Section 2 of this Agreement in connection with a termination of your employment that would otherwise have been
payable at any time during the six-month period immediately following such termination of employment shall not be paid prior to, and shall instead be payable in a lump sum as soon as practicable following, the expiration of such six-month period. In
the event of death during such six-month period, upon provision to the Company of a signed general release of all claims against the Company and its affiliates in a form acceptable to the Company, Executive’s estate will receive the severance
benefits described in this paragraph. 
 4. Successors and Binding Agreement. 
 (a) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise, including,
without limitation, any successor due to a Change in Control) to the business or assets of the Company, by agreement in form and substance reasonably satisfactory to Executive, expressly to assume and agree to perform this Agreement in the same
manner and to the same extent the Company would be required to perform if no such succession had taken place. This Agreement will be binding upon and inure to the benefit of the Company and any successor to the Company, including, without
limitation, any persons directly or indirectly acquiring the business or assets of the Company in a transaction constituting a Change in Control (and such successor shall thereafter be deemed the “Company” for the purpose of this
Agreement), but will not otherwise be assignable, transferable or delegable by the Company. 
  

 4 

 (b) This Agreement will inure to the benefit of and be enforceable by Executive’s personal or
legal representatives, executors, administrators, successors, heirs, distributees and legatees. 
 (c) This Agreement is personal in
nature and neither of the parties hereto shall, without the consent of the other, assign, transfer or delegate this Agreement or any rights or obligations hereunder except as expressly provided in Sections 4(a) and 4(b). Without limiting the
generality or effect of the foregoing, Executive’s right to receive payments hereunder will not be assignable, transferable or delegable, whether by pledge, creation of a security interest, or otherwise, other than by a transfer by
Executive’s will or by the laws of descent and distribution and, in the event of any attempted assignment or transfer contrary to this Section 4(c), the Company shall have no liability to pay any amount so attempted to be assigned,
transferred or delegated. 
 5. Amendment or Termination of Agreement. This Agreement may be changed or terminated only upon
the mutual written consent of the Company and Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company after such change or termination has been approved by the
Board. 
 6. Entire Agreement. This Agreement constitutes the entire agreement of the parties hereto with respect to the
subject matter hereof and supersedes all prior representations, understandings, undertakings or agreements (whether oral or written and whether expressed or implied) of the parties with respect to severance and benefits payable to Executive
following a termination of his employment in connection with a Change in Control (the “Change of Control Severance Provisions”). [No provisions of the Employment Agreement other than the Change of Control Severance Provisions are
superseded by this Agreement, and the Employment Agreement shall otherwise remain in full force and effect.] 
 7. Notices. For
all purposes of this Agreement, all communications, including without limitation notices, consents, requests or approvals, required or permitted to be given hereunder will be in writing and will be deemed to have been duly given when hand delivered
or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or five business days after having been mailed by United States registered or certified mail, return receipt requested, postage prepaid, or three business
days after having been sent by a nationally recognized overnight courier service such as FedEx, UPS, or DHL, addressed to the Company (to the attention of the Secretary of the Company) at its principal executive office and to Executive at his
principal residence, or to such other address as any party may have furnished to the other in writing and in accordance herewith, except that notices of changes of address shall be effective only upon receipt. 
 8. Validity. If any provision of this Agreement or the application of any provision hereof to any person or circumstances is held invalid,
unenforceable or otherwise illegal, the remainder of this Agreement and the application of such provision to any other person or circumstances will not be affected, and the provision so held to be invalid, unenforceable or otherwise illegal will be
reformed to the extent (and only to the extent) necessary to make it enforceable, valid or legal. 
  

 5 

 9. Governing Law; Jurisdiction. The laws of the state of California shall govern the
interpretation, validity and performance of the terms of this Agreement, regardless of the law that might be applied under principles of conflicts of law. Any suit, action or proceeding against Executive, with respect to this Agreement, or any
judgment entered by any court in respect of any of such, may be brought in any court of competent jurisdiction in the State of California, and Executive hereby submits to the jurisdiction of such courts for the purpose of any such suit, action,
proceeding or judgment. 
 10. Miscellaneous. No provision of this Agreement may be modified, waived or discharged unless such
waiver, modification or discharge is agreed to in writing signed by Executive and the Company. No waiver by either party hereto at any time of any breach by the other party hereto or compliance with any condition or provision of this Agreement to be
performed by such other party will be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement constitutes the entire agreement of the parties with respect to the subject matter
hereof and supersedes any and all prior agreements of the parties with respect to such subject matter. No agreements or representations, oral or otherwise, expressed or implied with respect to the subject matter hereof have been made by either party
which are not set forth expressly in this Agreement. References to Sections are to references to Sections of this Agreement. 
 11.
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same agreement. 
 12. Section 409.A. The parties acknowledge and agree that, to the extent applicable, this Agreement shall be interpreted in accordance
with, and the parties agree to use their best efforts to achieve timely compliance with, Section 409A of the Code, and the Department of Treasury Regulations and other interpretive guidance issued thereunder, including, without limitation, any
such regulations or other guidance that may be issued after the Effective Date. Notwithstanding any provision of this Agreement to the contrary, in the event that the Company determines that any amounts payable hereunder would otherwise be taxable
to Executive under Section 409A, the Company may adopt such limited amendments to this Agreement and appropriate policies and procedures, including amendments and policies with retroactive effect, that the Company reasonably determines are
necessary or appropriate to comply with the requirements of Section 409A and thereby avoid the application of penalty taxes under such Section. 
 [signature page follows] 
  

 6 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the
date first above written. 
  

			
	MAP PHARMACEUTICALS, INC.
	
	  

	By:	 	  

	Title:	 	  

	
	  

	[Executive]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]